These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 25693783)

  • 1. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
    Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
    J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
    J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
    J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
    Rich P; Goldblum O; Disch D; Lin CY; Merola JF; Elewski B
    J Drugs Dermatol; 2020 Aug; 19(8):741-746. PubMed ID: 32845588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3.
    Egeberg A; Kristensen LE; Vender R; Zaheri S; El Baou C; Gallo G; Riedl E; Schuster C
    Acta Derm Venereol; 2022 Oct; 102():adv00787. PubMed ID: 36121210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
    Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
    Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials.
    Elewski B; Rich P; Lain E; Soung J; Lewitt GM; Jacobson A
    J Dermatolog Treat; 2022 Feb; 33(1):261-265. PubMed ID: 32250714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
    Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
    Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
    Blauvelt A; Gooderham M; Iversen L; Ball S; Zhang L; Agada NO; Reich K
    J Am Acad Dermatol; 2017 Nov; 77(5):855-862. PubMed ID: 28917383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
    Leonardi C; Maari C; Philipp S; Goldblum O; Zhang L; Burkhardt N; Ball S; Mallbris L; Gonzalez P; Fernández-Peñas P; Puig L
    J Am Acad Dermatol; 2018 Nov; 79(5):824-830.e2. PubMed ID: 29803904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
    N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
    Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
    N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.